AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.
AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.
AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 4
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
KV Pharma Acquires Rights To Makena From Hologic For US$199.5 Million 15
Private Equity 16
GTCR Invests In Cord Blood Registry 16
MSMB Capital Management To Acquire AMAG Pharma 17
Partnerships 18
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 18
Licensing Agreements 19
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 19
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
Equity Offering 23
AMAG Pharma Raises USD260 Million in Public Offering of Shares 23
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 26
KV Pharma Completes Private Placement Of Shares For US$260.9 Million 27
K-V Pharma Completes Private Placement For US$0.21 Million 27
KV Pharma Completes Private Placement For US$32 Million 28
Debt Offering 29
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 31
K-V Pharma Completes Private Placement Of Senior Secured Notes Due 2015 For US$225 Million 33
Asset Transactions 34
Perrigo to Acquire Womens Healthcare Business from Lumara Health for USD82 Million 34
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 35
Acquisition 36
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 36
AMAG Pharma Acquires Lumara Health for USD712 Million 38
AMAG Pharma Plans For Sale Of The Company 40
Zydus Pharma Completes Acquisition Of Nesher Pharma From KV Pharma 41
AMAG Pharmaceuticals Inc - Key Competitors 43
Key Employees 44
Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 47
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 49
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 52
Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 54
Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 56
May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 58
Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 60
Corporate Communications 62
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 62
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 63
Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 64
Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 65
Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 66
Government and Public Interest 67
Dec 15, 2016: AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research 67
Product News 68
Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 68
Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 69
Product Approvals 70
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 70
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 72
Clinical Trials 73
Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena 73
Other Significant Developments 74
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
List Of Tables
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
KV Pharma Acquires Rights To Makena From Hologic For US$199.5 Million 15
GTCR Invests In Cord Blood Registry 16
MSMB Capital Management To Acquire AMAG Pharma 17
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 18
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 19
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21
AMAG Pharma Raises USD260 Million in Public Offering of Shares 23
AMAG Pharma Raises USD201 Million in Public Offering of Shares 24
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 26
KV Pharma Completes Private Placement Of Shares For US$260.9 Million 27
K-V Pharma Completes Private Placement For US$0.21 Million 27
KV Pharma Completes Private Placement For US$32 Million 28
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 31
K-V Pharma Completes Private Placement Of Senior Secured Notes Due 2015 For US$225 Million 33
Perrigo to Acquire Womens Healthcare Business from Lumara Health for USD82 Million 34
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 35
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 36
AMAG Pharma Acquires Lumara Health for USD712 Million 38
AMAG Pharma Plans For Sale Of The Company 40
Zydus Pharma Completes Acquisition Of Nesher Pharma From KV Pharma 41
AMAG Pharmaceuticals Inc, Key Competitors 43
AMAG Pharmaceuticals Inc, Key Employees 44
AMAG Pharmaceuticals Inc, Other Locations 46
AMAG Pharmaceuticals Inc, Subsidiaries 46
List Of Figures
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
RELATED REPORTS
Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) - Drugs in Development, 2021
Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) -
View ReportAMAG Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
AMAG Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines AMAG Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,
View ReportRocket Pharmaceuticals Inc (RCKT) - Financial and Strategic SWOT Analysis Review
Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapeutics for the treatment of glaucoma and
View ReportSunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review
Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
